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Abstract
Background: Cryptococcus gattii is a fungal pathogen causing an emerging outbreak in the United States Pacific Northwest
(PNW). Treatment guidelines for cryptococcosis are primarily based on data from C. neoformans infections; applicability to
PNW C. gattii infection is unknown. We evaluated the relationship between initial antifungal treatment and outcomes for
PNW C.gattii patients.
Methods: Cases were defined as culture-confirmed invasive C. gattii infections among residents of Oregon and Washington
States during 2004–2011. Clinical data were abstracted from medical records through one year of follow-up. Recommended
initial treatment for central nervous system (CNS), bloodstream, and severe pulmonary infections is amphotericin B and 5-
flucytosine; for non-severe pulmonary infections, recommended initial treatment is fluconazole. Alternative initial treatment
was defined as any other initial antifungal treatment.
Results: Seventy patients survived to diagnosis; 50 (71%) received the recommended initial treatment and 20 (29%)
received an alternative. Fewer patients with pulmonary infections [21 (64%)] than CNS infections [25 (83%)] received the
recommended initial treatment (p = 0.07). Among patients with pulmonary infections, those with severe infections received
the recommended initial treatment less often than those with non-severe infections (11% vs. 83%, p,0.0001). Eight patients
with severe pulmonary infections received alternative initial treatments; three died. Four patients with non-severe
pulmonary infections received alternative initial treatments; two died. There was a trend towards increased three-month
mortality among patients receiving alternative vs. recommended initial treatment (30% vs. 14%, p = 0.12), driven primarily
by increased mortality among patients with pulmonary disease receiving alternative vs. recommended initial treatment
(42% vs. 10%, p = 0.07).
Conclusions: C.gattii patients with pulmonary infections – especially severe infections – may be less likely to receive
recommended treatment than those with CNS infections; alternative treatment may be associated with increased mortality.
Reasons for receipt of alternative treatment among C.gattii patients in this area should be investigated, and clinician
awareness of recommended treatment reinforced.
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Introduction
Cryptococcus spp. are basidiomycetous yeast, with two species, C.
gattii and C. neoformans, causing nearly all human cryptococcal
infections [1–3]. C. neoformans typically causes disease in immuno-
compromised individuals [4,5], and is an important and common
cause of opportunistic infections in HIV/AIDS patients worldwide
[6–8]. In contrast, C. gattii has historically been characterized as a
rare pathogen, with disease confined to tropical and subtropical
climates, particularly the highly endemic regions of Australia and
Papua New Guinea [9,10]. Until recently, C. gattii was thought to
affect primarily immunocompetent persons living in these regions
[11–15].
Since 2004, an outbreak of C. gattii infections has been
documented in the United States Pacific Northwest states of
Oregon and Washington [16]. The outbreak in these states is
thought to have originated in, and spread from, British Columbia,
Canada, where infections caused by the same C. gattii genetic types
have been documented since 1999 [17,18]. Genetic sequencing
has demonstrated that C. gattii can be divided into four molecular
types, denoted as VGI, VGII, VGIII and VGIV [19]; these
molecular types can be distinguished by various genetic techniques
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and have different geographic distributions [20–23]. The emer-
gence of C. gattii infections in Oregon, Washington State, and
British Columbia is primarily due to the clonal expansion of three
genetic subtypes belonging to the molecular type VGII, called
VGIIa, VGIIb, and VGIIc [24–26]; these have been referred to as
‘outbreak-strain’ subtypes. Outbreak-strain subtypes are different
from those found in historically endemic Australia and Papua New
Guinea (and other areas of the world), where infections are most
frequently caused by nonclonal strains of C. gattii, most commonly
VGI [11,27–29]. Clinical differences between C. gattii infections in
the United States Pacific Northwest and historically endemic areas
have been described. While C. gattii in historically endemic areas
has been reported to infect primarily immunocompetent persons,
causing meningoencephalitis [11,27,28,30–32], C. gattii infections
in Oregon and Washington State occur frequently in immuno-
compromised persons and present most often as respiratory illness
[33].
Current guidelines for the management and treatment of
cryptococcal disease from the Infectious Disease Society of
America (IDSA) recommend antifungal treatment that varies by
site and severity of infection [34]. The recommended initial
treatment (RIT) for severe pulmonary disease, central nervous
system (CNS) disease, and other disseminated disease (such as
cryptococcemia) is amphotericin B (AMB) and 5-flucytosine (5FC);
for non-severe pulmonary disease, the RIT is fluconazole, with
itraconazole and posaconazole as acceptable second-line agents
[34]. These recommendations are unchanged from previous IDSA
guidelines for cryptococcosis, released in 2000, which were
available when the majority of patients in this report were
diagnosed [35].
Although IDSA guidelines for treatment of cryptococcal disease
are based primarily on data from C. neoformans infections in HIV
and solid organ transplant patients, these guidelines are intended
to apply to patients with C. neoformans or C. gattii infections. A
limited number of C. gattii-specific recommendations were
included for the first time in the 2010 IDSA guidelines and are
based on data from C. gattii infections in historically endemic areas,
the only data available at the time of the guideline-writing [34].
These recommendations pertain mainly to patients with crypto-
coccomas, which previous data have suggested are more common
in patients infected with C. gattii than C. neoformans [31], and
include consideration of surgery for patients with large crypto-
coccomas, increased radiologic and follow-up evaluations for those
with cryptococcomas or hydrocephalus, and possible use of AMB/
5FC in patients with large and/or multiple pulmonary crypto-
coccomas [34].
Given the genotypic and clinical differences between C. gattii
infections in the United States Pacific Northwest and cryptococcal
infections due to either C. gattii from historically endemic areas or
C. neoformans, applicability of the current IDSA guidelines to C.
gattii patients in Oregon and Washington State is unknown. We
conducted a retrospective cohort study of C. gattii infections
reported in these states to evaluate the relationship between IDSA
guideline-recommended initial antifungal treatment and clinical
outcomes.
Methods
Case Definition and Case-finding
A case was defined as culture-confirmed C. gattii infection
reported to CDC during January 1, 2004 to October 1, 2011, in a
person residing in Oregon or Washington State. Patients were
identified from existing passive laboratory-based surveillance
systems that capture culture-confirmed C. gattii infections in these
states. Although reporting is passive, C. gattii has been notifiable in
Oregon since 2011, and in Washington State (as a rare disease of
public health importance) since 2006. This investigation was
conducted as part of routine public health practice in response to
an ongoing outbreak of C. gattii in the United States Pacific
Northwest. This investigation was reviewed and designated as
non-research by a CDC ethics liaison, informed consent was not
obtained from patients, and the study was deemed exempt from
formal institutional review board evaluation.
Data Collection
We abstracted data from case-patient medical records using a
standardized form. Information about demographics, underlying
medical conditions, current medications, signs and symptoms,
laboratory and radiologic studies, and treatments and procedures
performed secondary to C. gattii diagnosis were recorded. Data
were collected from case-patients’ initial visits and at two, six, 12,
24 and 52 weeks of follow-up. Death databases were searched to
identify any deaths that occurred during follow-up. All data were
entered into a Microsoft Access database.
Definition of Terms
We limited our analyses to case-patients with invasive C. gattii
disease, which we defined as infection of any of the deep organs or
body tissues, including blood. We excluded superficial infections,
including skin, throat and urinary tract infections without evidence
of involvement of other organs, due to the small number and
absence of specific treatment recommendations for these infections
[34]. Additionally, we excluded children ,15 years, as the IDSA
guidelines for children differ to some extent from those for adults
[34,35].
Infections were categorized in a hierarchy, based on site of
infection. Infections were categorized as ‘bloodstream’ if the
patient had at least one positive blood culture for C. gattii,
regardless of other positive cultures. Infections were categorized as
‘CNS’ if cerebrospinal fluid (CSF) or brain tissue cultures yielded
C. gattii in the absence of documented bloodstream infection.
Infections were also categorized as ‘CNS’ if the case-patient had a
positive CSF cryptococcal antigen result or had brain tissue
histopathology consistent with cryptococcal disease and a positive
culture for C. gattii from a body site outside the CNS (not including
blood). Infections were categorized as ‘pulmonary’ if respiratory
specimens (sputum, bronchoalveolar lavage) or lung tissue cultures
yielded C. gattii in the absence of documented bloodstream or CNS
infection. Bloodstream infections were categorized separately from
other invasive C. gattii infections (e.g. CNS infections) due to the
high mortality that was observed in patients with fungemia due to
C. gattii. Pulmonary infections were further categorized as either
‘non-severe’ or ‘severe’. Severe pulmonary infections were defined
as those in which the patient required intensive care unit
admission for treatment of pulmonary disease. Non-severe
pulmonary infections included all other pulmonary infections.
We defined immunocompromise as the presence of any of the
following documented conditions or medications in a patient at
initial presentation for cryptococcal disease: active hematologic
malignancy, recent neutropenia (defined as absolute neutrophil
count ,500 cells/mL in the 30 days before cryptococcal diagno-
sis), history of allogeneic or autologous stem cell transplant, solid
organ transplant, cytotoxic chemotherapy, HIV infection, auto-
immune disease, oral or parenteral steroid use at a dose .5 mg/
day during the past year, or current use of other drugs that
suppress the immune system (i.e. methotrexate, tumor necrosis
factor-a inhibitor). We defined major medical comorbidities as
Treatment and Outcomes of Cryptococcus gattii
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existence of pulmonary, cardiac, liver or renal disease, document-
ed diabetes, or immunocompromise as defined above.
RIT was defined, based on 2010 and 2000 IDSA guidelines, as
the administration of AMB/5FC for CNS infections, severe
pulmonary infections, and bloodstream infections, and adminis-
tration of an azole drug (fluconazole, itraconazole, or posacona-
zole) for patients with non-severe pulmonary infections [34,35].
Alternative initial treatment (AIT) included any other initial
antifungal treatment for the respective infections. Recognizing that
clinical information obtained during the days following a patient’s
diagnosis with cryptococcosis might impact clinical decision-
making, we assessed whether treatment was RIT or AIT at four
days after a diagnosis of C.gattii was made. For example, for
patients with severe pulmonary disease for whom RIT included
AMB/5FC, an alternate treatment during days 1–4 after diagnosis
did not result in an AIT classification if the patient was switched to
AMB/5FC by day five. However, continued AIT past the four-day
mark would result in a patient being designated as receiving AIT.
Data Analysis
Comparisons of proportions were evaluated with the x2 test; the
Fisher’s exact test was used when one or more cell counts were,5.
Comparison of medians was done with the Wilcoxon-rank-sum
test. All analysis was done in SAS version 9.3 (SAS Institute Inc.,
Cary, NC).
Results
Demographics
We identified 74 patients with invasive C. gattii infections: 19
(26%) in Washington and 55 (74%) in Oregon. Four patients died
before diagnosis of C. gattii infection (3, 7, 7, and 12 days before
diagnosis); two had bloodstream infections and two had pulmo-
nary infections (both severe).
Seventy (95%) patients survived to diagnosis and were included
in further analysis. Median time from symptom onset to diagnosis
was 34 (range: 3–351) days. Median patient age was 54 (range: 15–
96) years; 36 (51%) were female. Sixty-five (93%) patient isolates
were identified as outbreak-strain VGII subtypes, with 43 (61%)
VGIIa, 17 (24%) VGIIc, and five (7%) VGIIb; of the remaining
isolates, four (6%) were molecular type VGI and one (1%) was
VGIII. Fifty-seven (81%) patients were hospitalized at the time of
cryptococcal diagnosis. Of the 69 patients with immune status
documented, 35 (51%) were immunocompromised at presenta-
tion. The most common immunocompromising conditions were
systemic steroid use (24 patients; 69%) and autoimmune disease
(13 patients; 37%). Among all 70 patients who survived to
diagnosis, 3 (4%) patients had documented HIV infection; 36
(51%) additional patients had documented testing for HIV
infection at the time of diagnosis of C. gattii infection and were
found to be negative. Non-immunocompromising comorbid
conditions were also common: 29 (41%) patients had cardiovas-
cular disease, 16 (23%) had diabetes, and 14 (20%) had underlying
respiratory disease. Nine (13%) patients were otherwise healthy (no
immunocompromise and no comorbid conditions). Thirteen
(19%) patients died within three months of diagnosis (Table 1).
Sites and Severity of Infection
For the purposes of this analysis, 33 (47%) of the 70 patients
surviving to diagnosis were categorized as having pulmonary
infections, 30 (43%) were categorized as having CNS infections,
and seven (10%) were categorized as having bloodstream
infections. Of the 33 patients with pulmonary infections, 24
(73%) infections were non-severe and nine (27%) were severe
(Table 1). Table 2 shows all documented sites of C. gattii infection
for all patients and the infection-type categorization used during
this analysis.
While most immunocompromised patients had pulmonary
infections (20/35, 57%), most immunocompetent patients had
CNS infections (18/34, 53%). Time from symptom onset to
diagnosis of C. gattii infection was significantly longer among
patients with pulmonary infections (50 days) than those with either
CNS (24 days) (p = 0.005) or bloodstream infections (27 days)
(p = 0.02). There were no differences in immune status between
patients with bloodstream infections and either pulmonary or CNS
infections.
Treatment and Outcomes
Of the 70 patients surviving to diagnosis, 50 (71%) received RIT
and 20 (29%) received AIT. Three (43%) patients with blood-
stream infections received AIT, compared with 12 (36%) patients
with pulmonary infections and five (17%) patients with CNS
infections (Table 3). More patients with pulmonary (36%) than
CNS (17%) infections received AIT, though this difference was
borderline significant (p = 0.07) (Table 3). Patients with blood-
stream infections were not significantly more likely than those with
either pulmonary (p = 1.0) or CNS (p = 0.16) infections to receive
AIT; however, the small number of patients with bloodstream
infections likely limited our ability to compare these groups.
Among patients with pulmonary infections, those with severe
infections were more likely to receive AIT than those with non-
severe infections (89% vs. 17%, p,0.001) (Table 3). Of the eight
patients with severe pulmonary infections receiving AIT, seven
(88%) received an azole only and one (12%) received AMB
monotherapy (no 5FC given) (Table 4). Of the four patients with
non-severe pulmonary infections who received AIT, one (25%)
received AMB monotherapy, one (25%) received caspofungin and
voriconazole, and two (50%) received no treatment (Table 4). All
five patients with CNS infections and all three patients with
bloodstream infections who received AIT received AMB mono-
therapy (no 5FC given) (Table 4).
Thirteen (19%) of the 70 patients surviving to diagnosis died
within three months. Three-month mortality was highest for
patients with bloodstream infections (3/7; 43%), next-highest for
patients with pulmonary infections (7/33; 21%), and lowest for
patients with CNS infections (3/30; 10%). Overall, three-month
mortality was non-significantly higher among patients receiving
AIT compared with those receiving RIT (30% vs. 14%, p= 0.12),
driven primarily by a trend in increased mortality among patients
with pulmonary infections receiving AIT versus RIT (42% vs.
10%, p= 0.07) (Table 3). The increased three-month mortality
among patients with pulmonary disease receiving AIT versus RIT
was observed both for patients with severe (38% vs. 0%, p= 1.0)
and non-severe pulmonary disease (50% vs. 10%, p= 0.12)
(Table 3). RIT was not associated with increased mortality among
patients with CNS or bloodstream infections (p = 1.0 for both). No
association was found between three-month mortality and
immunocompromising conditions; nine (26%) immunocompro-
mised patients died within three months of their diagnosis,
compared with four (12%) immunocompetent patients (p = 0.22).
Similarly, no association was found between three-month mortal-
ity and presence of any pre-existing major medical comorbidity;
ten (16%) patients with pre-existing comorbidities died within
three months of their diagnosis, compared with three (33%)
without any pre-existing condition (p= 0.35). No association was
found between three-month mortality and time to diagnosis
(p = 0.68).
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Discussion
We describe the initial antifungal treatments utilized in United
States Pacific Northwest C. gattii infections and subsequent patient
outcomes. Patients in this analysis, as previously described [16,33],
were frequently immunocompromised or had serious comorbid
conditions and most commonly presented with pulmonary disease.
The overall case-fatality rate for this cohort was high (19%). We
found that while a substantial minority of patients did not receive
IDSA guideline-recommended initial therapy, the receipt of
alternative initial treatments was not equally distributed across
all C. gattii infections. Fewer patients with pulmonary infections
compared with central nervous system infections received IDSA
guideline-recommended initial therapy. Among patients with
isolated pulmonary infections, fewer with severe pulmonary
infections received recommended initial therapy compared with
those persons with non-severe infections. Among the patients who
received alternate initial treatment, most were ‘under-treated’,
either through failure to receive 5-flucytosine with amphotericin B
(for patients with CNS, bloodstream and severe pulmonary
infections), or failure to receive any treatment (for patients with
non-severe pulmonary infections). Receipt of an alternative initial
therapy was associated with a non-significant trend towards
increased mortality (approximately 30% excess mortality) in the
three months after diagnosis, particularly among patients with
pulmonary infections.
There are a number of reasons why IDSA-recommended initial
therapy might not have been used with patients in this cohort.
While infectious disease clinicians are likely to be aware of the
Table 1. Characteristics of patients with invasive Cryptococcus gattii infection in United States Pacific Northwest who survived to
diagnosis (N = 70).
Characteristic Sub-category N (%)
Female 36 (51)
VGII molecular type isolatesa 65 (93)
Median age (range) in years 54 (15–96)
Immunocompromiseb 35 (51)
Systemic steroid usec 24 (69)
Autoimmune diseasec 13 (37)
HIVc 3 (4)
Hospitalized at cryptococcal diagnosis 57 (81)
Medical co-morbidityc Cardiovascular disease 29 (41)
Diabetes 16 (23)
Respiratory disease 14 (20)
Otherwise healthy (no immunocompromise or comorbid conditions) 9 (13)
Site of infection Pulmonary 33 (47)
CNS 30 (43)
Bloodstream 7 (10)
Severity of pulmonary infection Severe 9 (27)
Non-severe 24 (73)
Median time from symptom onset to diagnosis in days 34 (3–351)
Died within 3 months of diagnosis 13 (19)
aVGII molecular type isolates include isolates from the three outbreak genotypes, VGIIa, VGIIb, and VGIIc.
bn = 69.
cCategories not mutually exclusive.
doi:10.1371/journal.pone.0088875.t001
Table 2. All documented sites of Cryptococcus gattii infection and categorization for analysis*.
Body sites found to have Cryptococcus gattii
infection during clinical workup
Categorization of infection
type for analysis Number of patients
Lungs Pulmonary 33
Blood Bloodstream 2
Blood/Central Nervous System Bloodstream 4
Blood/Central Nervous System/Lungs Bloodstream 1
Central Nervous System/Lungs CNS 5
Central Nervous System CNS 25
*Total patients in analysis with pulmonary infection, 33; with bloodstream infection, 7; with CNS infection, 30.
doi:10.1371/journal.pone.0088875.t002
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IDSA guidelines for cryptococcal disease, many patients are
initially treated by clinicians without formal infectious disease
training who may not be aware of the IDSA guidelines.
Specifically, they may not be aware that severe pulmonary
cryptococcosis should be treated in the same way as central
nervous system cryptococcosis, leading to under-treatment of
patients with severe pulmonary infections. Additionally, as C. gattii
infections in the United States Pacific Northwest appear to be
clinically different from C. gattii infections in other areas of the
world, some clinicians who are aware of the IDSA guidelines in
Oregon and Washington State may initially deviate from IDSA-
recommended therapy due to concerns about the generalizability
of the guidelines to their patients with C. gattii infection. Finally,
clinicians may not have used guideline-recommended initial
therapy due to matters beyond their control, such as patient
contraindications to medications, insurance restrictions, or drug
shortages. While we were unable to evaluate why clinicians chose,
in a minority of patients, to pursue alternative treatments, our data
suggests that there might be some benefit in adhering to IDSA
guideline-recommended initial treatment in United States Pacific
Northwest C. gattii patients, particularly those with pulmonary
disease. Further research into the reasons for use of alternative
initial treatment regimens is needed.
Pulmonary cryptococcosis presents a number of clinical
challenges in diagnosis and treatment. Unlike cryptococcal
meningitis, a common HIV-related opportunistic infection,
pulmonary cryptococcosis is much less-commonly-recognized
clinical entity, even among HIV-infected persons [36]. Diagnostic
delays for patients with pulmonary cryptococcosis, as seen in this
cohort, have been documented previously [37–40]. In terms of
treatment, while IDSA guidelines do specify use of antifungal
treatment for pulmonary cryptococcal infections – even mild
disease - and the use of amphotericin B and 5-flucytosine in
‘severe’ pulmonary disease [34,35], the quality of the evidence for
both recommendations is limited and based on ‘…opinions of
respected authorities…clinical experience, descriptive studies, or
reports of expert committees’ [34]. Unlike for cryptococcal
meningitis [41–44], no randomized controlled trials evaluating
best treatments for pulmonary cryptococcosis have been pub-
lished, and divergent opinions exist in the literature on the utility
and optimal type of antifungal treatment for these patients. Some
clinicians have suggested that asymptomatic or minimally symp-
tomatic pulmonary cryptococcosis in immunocompetent persons
requires no antifungal treatment at all [45,46], while others have
recommended azole drugs or amphotericin B in all cases [47,48].
In Australia, where guidelines recommend amphotericin B and 5-
flucytosine for all but mild/asymptomatic pulmonary cryptococ-
cosis, Chen et al recently published outcomes data on ten patients
with isolated pulmonary C. gattii infection. The majority of patients
were treated with amphotericin B and 5-flucytosine and only one
death was reported [49], raising the question of whether a more
aggressive approach might be warranted among patients with
pulmonary C. gattii infections. Larger-scale evaluations of patients
with pulmonary cryptococcal infections, including patients with C.
gattii infections from both previously-recognized endemic areas
and the United States Pacific Northwest, are needed to identify the
most appropriate treatment and improve outcomes.
We chose to evaluate initial antifungal treatment, and not
treatment later in the course of disease, for several reasons. First,
initial treatment, termed induction therapy, for cryptococcal
disease has been shown to have a strong impact on mortality.
Studies of HIV-infected patients during the early years of the HIV
epidemic demonstrated that induction therapy for cryptococcal
meningitis with fluconazole resulted in worse outcomes than
Table 3. Three-month mortality among patients by site of infection and by initial therapy received*.
Sites of infection n
Received
recommended
initial treatment
3-month mortality among
those receiving
recommended initial therapy
Received
alternative
initial therapy
3-month mortality among
those receiving alternative
initial therapy
All 70 50 (71%) 7 (14%) 20 (29%) 6 (30%)
By site of infection
Pulmonary 33 21 (64%) 2 (10%) 12 (36%) 6 (30%)
CNS 30 25 (83%) 3 (12%) 5 (17%) 0 (0%)
Bloodstream 7 4 (57%) 2 (40%) 3 (43%) 1 (50%)
By severity of pulmonary infection
Severe pulmonary 9 1 (11%) 0 (0%) 8 (89%) 4 (17%)
Non-severe 24 20 (83%) 2 (2%) 4 (17%) 2 (50%)
*Mortality measured from date of diagnosis; 4 patients died prior to diagnosis and receipt of antifungal therapy and are not included in this table.
doi:10.1371/journal.pone.0088875.t003
Table 4. Initial therapy received by Cryptococcus gattii patients.
Site of infection n Recommended initial therapy (n) Alternative initial therapy (n)
Severe pulmonary 9 Amphotericin B/5-flucytosine (1) Azole only (7); Amphotericin B only (1)
Non-severe pulmonary 24 Fluconazole (20) No treatment (2); Amphotericin B only (1);
caspofungin/voriconazole (1)
CNS 30 Amphotericin B/5-flucytosine (25) Amphotericin B only (5)
Bloodstream 7 Amphotericin B/5-flucytosine (4) Amphotericin B only (3)
doi:10.1371/journal.pone.0088875.t004
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induction with amphotericin B and 5-flucytosine [46]. Similarly,
treatment with amphotericin B alone (i.e., without 5-flucytosine)
has been shown to be inferior to combination amphotericin B and
5-flucytosine therapy for induction [44,45]. In addition, we
believed that selection of the initial antifungal drug is less likely
than subsequent treatment choices to be influenced by outside
factors (e.g., patient contraindications, adverse reactions) and
therefore more indicative of physician preference and knowledge.
However, it is possible that consolidation and maintenance drug
choices as well as duration of therapy also may influence patient
outcomes. Unfortunately, we were not able to evaluate that
relationship in this study.
This analysis included several limitations. First, this patient
group included those with C. gattii infections that were severe
enough to required hospitalization; thus, our findings regarding
treatment and outcomes are likely not applicable to mild, self-
limited pulmonary C. gattii infections. However, few of these mild
infections have been identified in this cohort and it is unclear how
frequently they occur. Second, due to the retrospective nature of
this study, not all patients received identical diagnostic testing (e.g.,
lumbar puncture, chest imaging, bronchoalveolar lavage); this may
have led to incomplete ascertainment of all sites of infection.
Third, these results are specific to patients with C. gattii infection in
the United States Pacific Northwest, and may not be generalizable
to patients with C. gattii infection in other areas. Finally, the
number of patients in our evaluation was small, particularly in
subgroup analyses. More data, ideally from prospective studies or
clinical trials, is needed to understand the relationship, if any,
between site of infection, initial antifungal treatment, and
outcomes in this population.
This is the first evaluation of the effect of initial antifungal
treatment on patient outcomes in the North American outbreak of
C. gattii. We show that a substantial minority of patients are not
getting the current guideline-recommended initial antifungal
therapy, which may be associated with improved outcomes.
Timely diagnosis and appropriate treatment for patients with C.
gattii infection will continue to be a clinical question as the
emergence of C. gattii in Oregon, Washington State, British
Columbia, and elsewhere continues. C. gattii infections in persons
with and without recent travel history to the United States Pacific
Northwest or British Columbia are increasingly being reported
throughout the United States [14,29,33,50,51]; this increased
visibility will raise more questions about the best treatment for
patients with C. gattii. As our identification of C. gattii infections
improves and diagnoses increase, as they are likely to do, careful
collection of treatment-related data from patients with these
infections will be vital to improving outcomes.
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